1. Concordant loss of fragile gene expression early in breast cancer development.
- Author
-
Guler, Gulnur, Uner, Aysegul, Guler, Nilufer, Shuang-Yin Han, Iliopoulos, Dimitrios, McCue, Peter, and Huebner, Kay
- Subjects
GENES ,GENE expression ,BREAST cancer ,TUMORS ,GENETIC regulation ,ONCOLOGY ,PATHOLOGY - Abstract
The FHIT and WWOX genes encompass the FRA3B and FRA16D fragile sites at chromosomes 3p14.2 and 16q23.3, respectively. Reduced Fhit and Wwox expression has been reported in approximately two-thirds of invasive breast tumors. Expression of these fragile gene products, as well as ErbB2 and p53, were evaluated immunohistochemically in 44 pure and 31 adjacent-to-invasive ductal carcinoma in-situ (DCIS) cases. Reduced Fhit and Wwox expression were observed in (i) 70% and 68% of pure DCIS; (ii) 52% and 55% of DCIS adjacent-to-invasive tumor cases; and (iii) 20% and 50% of adjacent normal tissue in pure DCIS cases. Reduced Wwox expression in adjacent normal tissue was observed in 30% of cases in the DCIS adjacent-to-invasive group. Reduced Fhit and Wwox expression was observed in 61% of adjoining invasive tumors. In all normal, pure DCIS, and DCIS adjacent-to-invasive lesions, Fhit and Wwox expression was positively associated ( P = 0.034, P = 0.042, P = 0.004, respectively) and in the invasive component there was a positive trend toward association ( P = 0.075). Fhit and Wwox were more frequently reduced in high-grade lesions in the DCIS adjacent-to-invasive ( P = 0.025, P = 0.004, respectively). In the pure DCIS group, there was a statistically significant negative association between Fhit and ErbB2 expression in DCIS ( P = 0.035). In summary, reduced Fhit and Wwox expression in in-situ breast cancer was associated, which may contribute to the high-grade DCIS–invasive tumor pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF